In recent years, managing diabetes has seen significant progress with the introduction of new medications. Among these, Sodium-glucose cotransporter-2 (SGLT2) inhibitors have gained popularity for their ability to help control blood sugar levels effectively.
These medications work by preventing the kidneys from reabsorbing glucose back into the bloodstream, causing excess sugar to be flushed out through urine. For many people with type 2 diabetes, this class of drugs has been a game-changer in keeping blood sugar levels under control.
However, a recent study by the U.S. Food and Drug Administration (FDA) has raised a serious concern. This research uncovered a rare but life-threatening infection associated with SGLT2 inhibitors called Fournier gangrene.
This condition affects the tissues around the external genitalia, the perineum, and the anal region. Although it is rare, when it does occur, it is extremely dangerous and can even be fatal if not treated quickly.
Fournier gangrene is a type of necrotizing fasciitis, a bacterial infection that destroys soft tissue. Symptoms often start with pain, redness, and swelling in the affected areas, sometimes accompanied by fever or a general feeling of being unwell.
As the infection progresses, the tissue begins to die, leading to severe complications. If not caught early, it can spread rapidly and require emergency surgery to remove dead tissue. In the worst cases, it can lead to sepsis, kidney damage, or even death.
The FDA’s study looked at data from March 1, 2013, to January 31, 2019, and found 55 cases of Fournier gangrene among people taking SGLT2 inhibitors. The patients ranged from 33 to 87 years old and included both men (39 cases) and women (16 cases).
What was particularly alarming was that the infections could develop anytime from just five days after starting the medication to over four years later. This means that even long-term users of these drugs are not completely safe from the risk.
To understand the significance of these findings, the researchers compared the rates of Fournier gangrene among users of SGLT2 inhibitors with those taking other common diabetes medications like metformin, insulin glargine, short-acting insulin, a combination of sitagliptin and metformin, and dulaglutide.
During a much longer observation period from 1984 to early 2019, only 19 cases of Fournier gangrene were reported in patients using these other drugs. The stark difference highlights that SGLT2 inhibitors seem to have a unique link to this dangerous infection.
This discovery is crucial because it brings attention to a risk that was not widely known before. Doctors prescribing SGLT2 inhibitors are now urged to watch for early symptoms of Fournier gangrene in their patients.
Symptoms like pain, tenderness, redness, or swelling in the genital or anal area, along with fever or fatigue, should not be ignored. Early detection and treatment are critical, as this infection progresses quickly and can cause life-threatening damage.
The study, led by Dr. Susan J. Bersoff-Matcha and her team, was published in the Annals of Internal Medicine. It serves as a reminder that while new medications like SGLT2 inhibitors can be highly effective for managing diabetes, they are not without risks.
Understanding these risks allows doctors and patients to be more vigilant, potentially catching serious side effects before they become life-threatening.
If you are taking an SGLT2 inhibitor, it’s important to know the warning signs of Fournier gangrene and to communicate with your healthcare provider if you notice anything unusual. This doesn’t mean you should stop your medication suddenly—doing so could cause dangerous spikes in blood sugar levels.
Instead, discuss any concerns with your doctor, who can help you weigh the benefits and risks and consider other options if necessary.
Overall, this research highlights the importance of ongoing monitoring and awareness in diabetes care. While SGLT2 inhibitors provide great benefits in controlling blood sugar, knowing the potential side effects can help ensure that the benefits outweigh the risks.
With careful attention and early intervention, many of these risks can be managed, allowing patients to continue benefiting from the latest advancements in diabetes treatment.
If you care about diabetes, please read studies about a cure for type 2 diabetes, and these vegetables could protect against kidney damage in diabetes.
For more information about diabetes, please see recent studies about bone drug that could lower risk of type 2 diabetes, and results showing eating more eggs linked to higher risk of type 2 diabetes.
Copyright © 2025 Knowridge Science Report. All rights reserved.
